.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
Daiichi Sankyo
Covington
McKinsey
Mallinckrodt
AstraZeneca
Julphar
Medtronic
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Patents Expiring in November 2019

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-003Jun 1, 2006ABRXYesYes► Subscribe► SubscribeY
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-002Jun 1, 2006ABRXYesNo► Subscribe► SubscribeY
Concordia Pharms IncORAPRED ODTprednisolone sodium phosphateTABLET, ORALLY DISINTEGRATING;ORAL021959-001Jun 1, 2006ABRXYesNo► Subscribe► SubscribeY
Spriaso LlcCODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATEchlorpheniramine maleate; codeine phosphateTABLET, EXTENDED RELEASE;ORAL206323-001Jun 22, 2015DISCNNoNo► Subscribe► SubscribeYTREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
NovartisGLEEVECimatinib mesylateCAPSULE;ORAL021335-002May 10, 2001DISCNYesNo► Subscribe► SubscribeY
NovartisGLEEVECimatinib mesylateCAPSULE;ORAL021335-001May 10, 2001DISCNYesNo► Subscribe► SubscribeY
NovartisGLEEVECimatinib mesylateTABLET;ORAL021588-002Apr 18, 2003ABRXYesYes► Subscribe► SubscribeY
NovartisGLEEVECimatinib mesylateTABLET;ORAL021588-001Apr 18, 2003ABRXYesNo► Subscribe► SubscribeY
Novartis Pharms CorpDUREZOLdifluprednateEMULSION;OPHTHALMIC022212-001Jun 23, 2008RXYesYes► Subscribe► SubscribeY
Takeda Pharms UsaDEXILANT SOLUTABdexlansoprazoleTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL208056-001Jan 26, 2016DISCNYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Colorcon
Covington
McKesson
Moodys
Harvard Business School
Accenture
Daiichi Sankyo
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot